Company updateBusiness Standard
Alembic bets on 30 US drug launches to sustain growth
Positive+11
GreyOak summary
Alembic Pharmaceuticals plans to sustain growth using a pipeline of approximately 30 US drug launches over the next 18 months. This strategy is necessary as exclusivity on its biggest recent drug expires this month. Managing Director Pranav Amin confirmed the company's reliance on these upcoming launches.
What it affects
- AlembicALEMBICLTDPositive +11
Rolling sentiment Positive +30
Source
Read the original at Business StandardMore Alembic news
- Alembic shares jump 15% after Q2 resultsMint · Results ·